Portal de Periódicos da CAPES

Transplantation of CD34+ Hematopoietic Progenitor Cells

1996; Taylor & Francis; Volume: 14; Issue: 6 Linguagem: Inglês

10.3109/07357909609076903

1532-4192

Ronald Berenson, Elizabeth J. Shpall, Karen Auditore‐Hargreaves, Shelly Heimfeld, Cindy Jacobs, Monica Schoelch Krieger,

Neuroblastoma Research and Treatments

We have developed an avidin-biotin immunoadsorption technique in conjunction with a monoclonal anti-CD34 antibody that is capable of selecting CD34+ progenitor cells from marrow and mobilized peripheral blood. Clinical studies with these CD34+ selected cells have shown that the cells are capable of rapid and durable engraftment. In addition, there is significantly less infusional toxicity to the patient because the volume in which the CD34+ selected cells are contained is much less than that of a typical marrow or apheresis buffy coat. Selection of CD34+ progenitor cells also offers other potential advantages, including T-cell depletion of allografts and tumor cell depletion of autografts. CD34+ selection can also be used to facilitate other manipulations of marrow and peripheral blood, including gene transfection, ex vivo stem cell expansion, tumor purging, and progenitor cell banking. Future graft engineering studies are expected to clarify these relationships and enable refinement of the graft to the point at which GVHD can be minimized, graft survival maximized, and relapse-free survival prolonged.